MLXIPL and liver cancer: In Black participants, homozygous carriers of MLXIPL Gln241His had a significantly higher risk of liver disease while heterozygous carriers showed a higher risk of malignant neoplasm of the liver and/or bile duct (adjusted odds ratio [aOR] 116.183 [95% CI: 11.586–1165.033]; aOR 5.210 [95% CI: 1.009–26.919], Supplemental Table S4, http://links.lww.com/HC9/A866).